Catalyst Pharma Files Preliminary Proxy for $4.1B Acquisition by Angelini Pharma
CPRX sits 64% above its 52-week low of $19.05.
Summary
Catalyst Pharmaceuticals has filed a preliminary proxy statement for its special shareholder meeting to vote on the $4.1 billion all-cash acquisition by Angelini Pharma at $31.50 per share.
Key Events · M&A and Partnerships · CPRX
-
Merger Agreement Details
Catalyst Pharmaceuticals is seeking shareholder approval for its acquisition by Angelini Pharma for $31.50 per share in cash, based on the merger agreement dated May 6, 2026.
-
Transaction Value & Premium
The deal is valued at approximately $4.1 billion, representing a 21% premium to Catalyst's unaffected closing share price on April 22, 2026.
-
Board Recommendation & Fairness Opinion
The Board of Directors unanimously recommends shareholders vote FOR the merger, supported by a fairness opinion from J.P. Morgan Securities LLC.
-
Executive Interests & Voting Agreements
Executive officers and directors have interests in the merger, including accelerated equity vesting, and have signed voting agreements to support the transaction.
Analysis · CPRX · Life Sciences
This preliminary proxy statement details the proposed acquisition of Catalyst Pharmaceuticals by Angelini Pharma for $31.50 per share in cash. The filing provides comprehensive information for shareholders to vote on the merger, including the board's unanimous recommendation, a fairness opinion from J.P. Morgan, and details on executive compensation related to the transaction. The deal, valued at approximately $4.1 billion, represents a significant premium to Catalyst's unaffected share price and is a critical step towards the transaction's completion, expected in Q3 2026.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.9% of the 1050 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CPRX was trading at $31.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $19.05 to $32.56. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.